

Ref: FOI/GS/ID 4567

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone
Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net

27 March 2018

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Diagnostic data on an MRI technique for men with suspected prostate cancer.

You asked:

1. Please tell us which Trust, Health Board or Health and Social Care Trust you are responding on behalf of?
2. What percentage of men receive mpMRI before biopsy as part of the initial diagnostic process using T2-weighted, diffusion-weighted (multi-b ADC and high/long b) and dynamic contrast enhanced (DCE) sequences?
3. What are your eligibility criteria/exclusion criteria for men to receive pre-biopsy mpMRI?
4. Are you using mpMRI before biopsy to rule some men out of biopsy as part of the initial diagnostic process?
5. What mpMRI scores and/or other clinical factors are used to rule men out of biopsy?
6. Do you intend to use mpMRI to rule men out of biopsy in the future?
7. How many men annually are referred?
8. If you are unable to provide numbers for question 6, please estimate the percentage of all men referred for b, c and d.
9. Do you carry out targeted biopsies in men with mpMRI lesions in addition to systematic biopsies?
(Please indicate with a X below)
If No, what are the reasons for not carrying this out? (e.g. expertise, equipment, don't believe it makes a difference)
10. If you do not currently carry out targeted biopsies, but wish to in the future, what are the current barriers to doing so?
(Please indicate with a X below)
11. Please indicate the number of urologists undertaking prostate MRI
12. How many scanners do you have available for mpMRI before biopsy?
Has this increased in the last 12 months?
13. What percentage of scanner time is dedicated to mpMRI before biopsy?

Trust response:

1. Maidstone and Tunbridge Wells NHS Trust

2. 95%

3.

Eligibility: fit for radical prostate cancer treatments

Exclusion: claustrophobia, implantable devices sensitive to MRI

4. No, but patients are taken off urgent care pathway. Patients are invited back to clinic with repeat PSA, and offered a biopsy if still elevated

5. PIRADS 1 or 2 AND PSA density <0.15 AND clinically benign

6. Depending on further evidence

7. How many men annually are referred?

(Please provide corresponding numbers)

a) On suspicion of prostate cancer? 757

b) Eligible for mpMRI? 378

c) Scanned? 452 total, 277 mpMRI eligible

d) Biopsied? 324, 194 mpMRI eligible

b) Eligible for mpMRI? 80%

c) Scanned? 75%

d) Biopsied? 40%

9.

Yes – cognitive/visual estimation

10. Not applicable

11. 3

12. 2

Has this increased in the last 12 months? Yes

13. 11% approx.